Phase 1 Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Quizartinib (Primary) ; Ziftomenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 16 Jan 2025 New trial record